Lundbeck

News

In advance of its NYC event, EVERSANA announces expanded AI agency capabilities and a partnership with brain health giant Lundbeck.

News

Lundbeck has completed patient randomisation in a pivotal trial of epilepsy candidate bexicaserin, one of its major growth hopes.

News

Lundbeck names Tarek Samad to replace its retiring R&D chief, Johan Luthman, and he is facing a tough task as the firm heads towards a patent cliff.

News

Lundbeck has reported positive trial results with Cushing's therapy asedebart, a key R&D prospect as it faces a patent cliff in the next few years.

News

Axsome's Auvelity has become the first non-antipsychotic therapy for agitation in patients with Alzheimer's disease to be approved by the FDA.

News

Lundbeck has appointed Markus Kede to the newly created role of chief AI officer, charged with driving its ambition to become a 'bionic' company.